Group 1: Company Performance - Organon closed at $18.10, with a +0.56% change from the previous day, lagging behind the S&P 500's gain of 0.77% [1] - The stock has decreased by 12.07% over the past month, underperforming the Medical sector's loss of 3% and the S&P 500's gain of 4.87% [1] Group 2: Upcoming Earnings - Organon's earnings report is expected on October 31, 2024, with projected earnings of $0.97 per share, indicating a year-over-year growth of 11.49% [2] - The Zacks Consensus Estimate for revenue is $1.56 billion, reflecting a 2.44% increase from the previous year [2] Group 3: Fiscal Year Estimates - For the entire fiscal year, earnings are estimated at $4.34 per share and revenue at $6.34 billion, showing changes of +4.83% and +1.28% respectively from the prior year [3] Group 4: Analyst Estimates - Recent changes to analyst estimates for Organon are important as they reflect short-term business trends and analysts' confidence in the company's performance [4] - The Zacks Rank system, which considers these estimate changes, provides an operational rating system for investors [5] Group 5: Zacks Rank and Valuation - Organon currently holds a Zacks Rank of 3 (Hold), with the Zacks Consensus EPS estimate having increased by 0.3% in the past month [6] - The company has a Forward P/E ratio of 4.14, significantly lower than the industry average of 20.29, and a PEG ratio of 0.75 compared to the industry average of 1.81 [7] Group 6: Industry Context - The Medical Services industry, which includes Organon, has a Zacks Industry Rank of 192, placing it in the bottom 24% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Organon (OGN) has been on a downward spiral lately with significant selling pressure. After declining 9.9% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier. Guide to Identifying Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is o ...

In the latest market close, Organon (OGN) reached $18.58, with a -1.33% movement compared to the previous day. This change lagged the S&P 500's 0.01% gain on the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq appreciated by 0.08%. Prior to today's trading, shares of the pharmaceutical company had lost 14.72% over the past month. This has lagged the Medical sector's loss of 3.6% and the S&P 500's gain of 1.21% in that time. Analysts and investors alike will be keeping a close ey ...

In the latest market close, Organon (OGN) reached $19.17, with a +0.74% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.4% for the day. On the other hand, the Dow registered a gain of 0.62%, and the technology-centric Nasdaq increased by 0.6%. The pharmaceutical company's stock has dropped by 15.31% in the past month, falling short of the Medical sector's loss of 2.27% and the S&P 500's gain of 1.71%. The investment community will be closely monitoring the ...

Company Performance - Organon (OGN) closed at $20.47, with a daily gain of +0.89%, outperforming the S&P 500's gain of 0.54% [1] - Over the past month, Organon's shares increased by 0.35%, lagging behind the Medical sector's gain of 4.37% and the S&P 500's gain of 4.86% [1] Upcoming Earnings - The upcoming earnings release is anticipated, with a forecasted EPS of $0.97, reflecting an 11.49% increase from the same quarter last year [2] - Revenue is projected at $1.56 billion, indicating a 2.44% rise from the equivalent quarter last year [2] Annual Estimates - For the annual period, earnings are expected to be $4.33 per share, with revenue anticipated at $6.34 billion, representing increases of +4.59% and +1.28% respectively from the previous year [3] Analyst Projections - Recent shifts in analyst projections should be monitored, as positive revisions indicate optimism regarding the company's business and profitability [4] Zacks Rank and Valuation - Organon currently holds a Zacks Rank of 4 (Sell), with the consensus EPS estimate remaining unchanged over the last 30 days [6] - The Forward P/E ratio for Organon is 4.68, significantly lower than the industry average of 22.16, and the PEG ratio stands at 0.85 compared to the industry average of 1.57 [7] Industry Context - The Medical Services industry, to which Organon belongs, has a Zacks Industry Rank of 173, placing it in the bottom 32% of over 250 industries [8]

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this pharmaceutical company have returned +1%, compared to the Zacks S&P 500 composite's +4% change. During this period, the Zacks Medical Services industry, which Organon falls in, has gained 1.2%. The key question now is: What could be the stock's future direction? Altho ...

Organon (OGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Shares of this pharmaceutical company have returned +0.6% over the past month versus the Zacks S&P 500 composite's +3.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 2.5% over this period. Now the key question is: Where could the stock be headed in the near term? Alt ...

Organon (OGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this pharmaceutical company have returned -2.5% over the past month versus the Zacks S&P 500 composite's -3.2% change. The Zacks Medical Services industry, to which Organon belongs, has gained 0.7% over this period. Now the key question is: Where could the stock be headed in the near term? Although media re ...

Organon (OGN) reported $1.61 billion in revenue for the quarter ended June 2024, representing a year-overyear decline of 0.1%. EPS of $1.12 for the same period compares to $1.31 a year ago. The reported revenue represents a surprise of -1.13% over the Zacks Consensus Estimate of $1.63 billion. With the consensus EPS estimate being $1.06, the EPS surprise was +5.66%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ne ...

Organon & Co. (NYSE:OGN) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Jennifer Halchak - Head of IR Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Umer Raffat - Evercore ISI Ethan Brown - JPMorgan David Amsellem - Piper Sandler Jason Gerberry - Bank of America Terence Flynn - Morgan Stanley Chris Shibutani - Goldman Sachs Operator Thank you for standing-by. My name is Mandeep, and I'll be your operator today. At this time, I'd like to welcome everyone to the ...